Kineta has been granted a patent for compounds that inhibit Usp14, which can be used to treat conditions associated with proteostasis dysfunction. The patent includes a specific compound structure outlined in Formula (VI). GlobalData’s report on Kineta gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kineta Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kineta, Peptide pharmacophores was a key innovation area identified from patents. Kineta's grant share as of September 2023 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11746098B2) discloses a compound with a specific chemical structure, referred to as Formula (VI). The compound can also exist as a pharmaceutically acceptable salt or solvate. In this structure, X1 is carbon, and both X2 and X4 are nitrogen.

The patent also claims variations of the compound, such as those where R2 is an optionally substituted cyclobutyl or a substituted cyclohexyl. Additionally, the compound can have R5 and R6 combining with X4 to form an optionally substituted 5-membered or 6-membered heterocyclic structure.

Another compound, referred to as Formula (VIII), is also described in the patent. This compound has X1 and X4 as nitrogen, and X2 as carbon. R1 in this compound can be a phenyl group substituted with at least one halogen. Furthermore, the phenyl group can be substituted with at least one C1-4 alkyl and at least one halogen. R2, R3, and R4 in this compound are each hydrogen. Similar to the previous compound, R5 and R6 can combine with X4 to form an optionally substituted 5-6-membered heterocyclic or heteroaryl structure.

The patent further includes pharmaceutical compositions containing the compounds described in Formula (VI), Formula (VIII), as well as Formula (IX) and Formula (X). These compositions consist of the compound or its pharmaceutically acceptable salt or solvate, along with a pharmaceutically acceptable carrier or excipient.

Overall, this patent presents a range of compounds with specific chemical structures and their variations, along with pharmaceutical compositions containing these compounds. These compounds and compositions may have potential applications in the field of pharmaceutical research and development.

To know more about GlobalData’s detailed insights on Kineta, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies